



Press release from Emotra AB (publ)

Göteborg, November 25, 2021

## **Emotra AB announces that an executive, a board member, and the company's largest shareholder intend to exercise their subscription warrants**

**Emotra AB ("Emotra" or "the Company") announce that its President, Daniel Poté, the chairman of the board, Claes Holmberg, and Emotra's largest shareholder, Maida Vale Capital AB, intend to exercise their subscription warrants in the TO 2 series ("The warrants") to purchase new shares.**

Insiders in the Company intend to exercise their subscription warrants with a value of MSEK 2.1, which corresponds to approximately 35 percent of the new issue value.

The exercise price for these warrants will be communicated by Emotra once this information is available. Each (1) subscription warrant in the TO 2 series gives its owner the right to purchase one (1) new share in Emotra during the period November 29 through December 13, 2021, except for banks, who have an earlier deadline. The last trading day for these subscription warrants is Thursday, December 9, 2021.

### **For further information about Emotra, please contact:**

Daniel Poté, President, telephone: +46 73 234 41 93, E-mail:

daniel@emotra.se [daniel@emotra.se](mailto:daniel@emotra.se)

---

*Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR<sup>®</sup>, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1,  
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)